Efficacy and safety of fondaparinux in patients with acute coronary syndromes

References

• Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation106, 1893–1900 (2002).
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation110, 282–292 (2004).
   Google Scholar
• Steg PG, Goldberg RJ, Gore JM et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am. J. Cardiol.90, 358–363 (2002).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Simoons ML, Fox KA et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J.23, 1809–1840 (2002).
   PubMed Web of Science ®Google Scholar
• van de Werf F, Ardissino D, Betriu A et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J.24, 28–66 (2003).
   PubMed Web of Science ®Google Scholar
• Petersen JL, Mahaffey KW, Hasselblad V et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA292, 89–96 (2004).
   PubMed Web of Science ®Google Scholar
• Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA292, 45–54 (2004).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Mehta SR et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation112, 3855–3867 (2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Xie C et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA293, 427–435 (2005).
   PubMed Web of Science ®Google Scholar
• Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med.354, 1477–1488 (2006).
   PubMed Web of Science ®Google Scholar
• White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet358, 1855–1863 (2001).
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Currie K, White K et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am. J. Cardiol.93, 288–293 (2004).
   PubMedGoogle Scholar
• Rao SV, O’Grady K, Pieper KS et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am. J. Cardiol.96, 1200–1206 (2005).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation114, 774–782 (2006).
   PubMed Web of Science ®Google Scholar
• Yang X, Alexander KP, Chen AY et al. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J. Am. Coll. Cardiol.46, 1490–1495 (2005).
   PubMed Web of Science ®Google Scholar
• Alexander KP, Chen AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA294, 3108–3116 (2005).
   PubMed Web of Science ®Google Scholar
• Gore JM, Spencer FA, Goldberg RJ et al. Use of heparins in non-ST-elevation acute coronary syndromes. Am. J. Med.120, 63–71 (2007).
   PubMedGoogle Scholar
• Alexander JH, Singh KP. Inhibition of Factor Xa: a potential target for the development of new anticoagulants. Am. J. Cardiovasc. Drugs.5, 279–290 (2005).
   PubMedGoogle Scholar
• Weitz JI, Linkins LA. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin. Investig. Drugs16, 271–282 (2007).
   PubMed Web of Science ®Google Scholar
• Herbert JM, Petitou M, Lormeau JC et al. SR 90107/Org 31540, a novel anti-Factor Xa antithrombotic agent. Cardiovasc. Drug Rev.15, 1–26 (1997).
   Web of Science ®Google Scholar
• Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemost.61, 397–401 (1989).
   PubMed Web of Science ®Google Scholar
• Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet.41(Suppl), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin. Drug Saf.4, 707–721 (2005).
   PubMedGoogle Scholar
• Turpie AG, Gallus AS, Hoek JA, Pentasaccharide Investigators 2001. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N. Engl. J. Med.344, 619–625 (2001).
   PubMed Web of Science ®Google Scholar
• Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med.345, 1305–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med.345, 1298–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet359, 1715–1720 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet359, 1721–1726 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med.162, 1833–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Lassen MR on behalf of the PENTHIFRA-PLUS investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. A multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med.163, 1337–1342 (2003).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Bauer KA, Caprini JA, Comp PP, Gent M, Muntz JE. Fondaparinux combined with intermittent pneumatic compression versus intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J. Thromb. Haemost. (2007) (In Press).
   Google Scholar
• Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br. J. Surg.92, 1212–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen AT, Davidson BL, Gallus AS et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br. Med. J.332, 325–329 (2006).
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med.140, 867–873 (2004).
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med.349, 1695–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N. Engl. J. Med.356, 2653–2655 (2007).
   PubMed Web of Science ®Google Scholar
• Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann. Pharmacother.40, 1383–1387 (2006).
   PubMedGoogle Scholar
• Simoons ML, Bobbink IW, Boland J et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes; The Pentasaccharide in Unstable Angina (PENTUA) study. J. Am. Coll. Cardiol.43, 2183–2190 (2004).
   PubMed Web of Science ®Google Scholar
• MICHELANGELO OASIS 5 Steering Committee. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic Factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am. Heart J.150, 1107 (2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med.354, 1464–1476 (2006).
   PubMed Web of Science ®Google Scholar
• Coussement PK, Bassand JP, Convens C et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur. Heart J.22, 1716–1724 (2001).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA295, 1519–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Steg PG, Granger CB et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation111, 1390–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Rupprecht H-J, vom Dahl J, Mehta SR. Benefit of fondaparinux in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention: insights from the OASIS-5 trial. Clin. Res. Cardiol.96(Suppl. 1), 869 (2007).
   Google Scholar
• Mehta RH, Roe MT, Chen AY et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch. Intern. Med.166, 2027–2034 (2006).
   PubMed Web of Science ®Google Scholar
• Mandelzweig L, Battler A, Boyko V et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur. Heart J.27, 2285–2293 (2006).
   PubMed Web of Science ®Google Scholar
• Fox KAA, Anderson FA, Dabbous OH et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart93, 177–182 (2007).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Granger CB, Mehta SR. Fondaparinux versus enoxaparin in acute coronary syndromes. N. Engl. J. Med.354, 2829–2830 (2006).
   PubMedGoogle Scholar
• Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology.Eur. Heart J.28, 598–660 (2007).
   Google Scholar
• Carruthers KF, Dabbous OH, Flather MD et al. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart91, 290–298 (2005).
   PubMed Web of Science ®Google Scholar
• Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med.167, 68–73 (2007).
   PubMedGoogle Scholar
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366, 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Gibbons RJ, Fuster V. Therapy for patients with acute coronary syndromes – new opportunities. N. Engl. J. Med.354, 1524–1527 (2006).
   PubMedGoogle Scholar
• Eagle KA, Goodman SG, Avezum A et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet359, 373–377 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen M, Gensini GF, Maritz F et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J. Am. Coll. Cardiol.42, 1348–1356 (2003).
   PubMed Web of Science ®Google Scholar
• Yatskar L, Selzer F, Feit F et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: Data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter. Cardiovasc. Interv.69, 961–966 (2007).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Kleiman NS, Fry E et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am. Heart J.141, 348–352 (2001).
   PubMedGoogle Scholar
• Buller CE, Pate GE, Armstrong PW et al. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can. J. Cardiol.22, 511–515 (2006).
   PubMedGoogle Scholar
• Madan M, Radhakrishnan S, Reis M et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION trial). Am. J. Cardiol.95, 1295–1301 (2005).
   PubMedGoogle Scholar
• Silber S, Albertsson P, Aviles FF et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J.26, 804–847 (2005).
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation113, e166–286 (2006).
   PubMedGoogle Scholar